Is KTTA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for KTTA. It does not provide personalized investment advice.

KTTA (Pasithea Therapeutics Corp. Common Stock) Stock Analysis - Financials

Pasithea Therapeutics Corp. Common Stock (KTTA) is a publicly traded Healthcare sector company. As of June 15, 2026, KTTA trades at $0.59 with a market cap of $19.75M and a P/E ratio of -0.20. KTTA moved -1.22% today. Year to date, KTTA is -54.18%; over the trailing twelve months it is -28.71%. Its 52-week range spans $0.28 to $4.39. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces KTTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are KTTA's key financials?

KTTA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KTTA recently traded at $0.59. Market cap is $19.75M. P/E ratio is -0.20. Revenue is $0.

KTTA Key Metrics

Key financial metrics for KTTA
Metric	Value
Price	$0.59
Market Cap	$19.75M
P/E Ratio	-0.20
EPS	$-2.91
Dividend Yield	0.00%
52-Week High	$4.39
52-Week Low	$0.28
Volume	106.00K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-20.43M
Gross Margin	0.00%

KTTA Analyst Consensus

1 analysts cover KTTA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.

Common questions about KTTA

What are KTTA's key financials?: KTTA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. KTTA recently traded at $0.59. Market cap is $19.75M. P/E ratio is -0.20. Revenue is $0.
Is KTTA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for KTTA. It does not provide personalized investment advice.